ReviewOncogene2021
Antibody-based cancer therapy.
Review in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Targeted Strategies for Treatment of Colorectal Cancer: Exploring the Use of Aptamers and Gold Nanoparticles.Molecules (Basel, Switzerland) · 2026Review
- Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.International journal of molecular sciences · 2026Review
- Functional screening of TCR-like antibodies using STAR-T cell library for cancer immunotherapy.EMBO molecular medicine · 2026Article
- Advanced Evaluation of T-Cell-Dependent Bispecific Antibodies Using Fluorescence Imaging and In Vivo Models.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Real-time and label-free monitoring of monoclonal antibody secretion rates using a PC-TIR biosensor.Biosensors & bioelectronics · 2025Article
- Nanoscale restructuring of the immune synapse with an engager enhances NK cell function.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Self-assembled nanoparticle vaccine comprised of multiple epitopes provides robust protective immunity against reoviruses in fish model.Cell communication and signaling : CCS · 2025Article
- DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Article
- ADCC: the rock band led by therapeutic antibodies, tumor and immune cells.Frontiers in immunology · 2025Review
- Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2025Review
- Turn TRAIL Into Better Anticancer Therapeutic Through TRAIL Fusion Proteins.Cancer medicine · 2025Review
- Synergistic integration of extracellular vesicles and metal-organic frameworks: unlocking new opportunities in disease diagnosis and therapy.Theranostics · 2025Review
- Advancing Immunotherapy in Pancreatic Cancer.International journal of molecular sciences · 2024Review
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2024Article
- Review
- Article
- Immunotherapies for locally aggressive cancers.Advanced drug delivery reviews · 2024Review
- Site-Selective Tyrosine Reaction for Antibody-Cell Conjugation and Targeted Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Over the past 25 years, antibody therapeutics have emerged as clinically and commercially successful pharmaceuticals, rapidly approaching 100 Food and Drug Administration approvals with combined annual global sales exceeding $100 billion. Nearly half of the marketed antibody therapeutics are used in oncology. These antibody-based cancer therapies can be broken down into three categories based on their different mechanisms of action, i.e., (i) natural properties, (ii) engagement of cytotoxic T cells, and (iii) delivery of cytotoxic payloads. Both natural and engineered properties of the antibody molecule are founded on its highly stable and modular architecture. In this review we provide an overview and outlook of the rapidly evolving landscape of antibody-based cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.